Introduction {#s1}
============

Acute myeloid leukemia (AML) refers to a group of hematopoietic neoplasms involving cells committed to the myeloid lineage. Acute promyelocytic leukemia (APL) is identified as the M3 subtype of AML. APL was first described in late 1950s in Norway and France as a hyperacute fatal illness associated with a hemorrhagic syndrome \[[@R01]\]. Within three decades, complete remission with chemotherapy like daunorubicin was reported \[[@R02]\]. Later, Dr. Zhen Wang described the efficacy of all-trans retinoic acid (ATRA) in APL patients, in 1980s \[[@R02]\]. In mid 1990s, arsenic trioxide (ATO) was added to the treatment regimen \[[@R03]\]. Over the past few years, APL has transformed from a highly fatal disease to a highly curable one. Majority of cases are characterized by a balanced translocation between chromosome 17 and chromosome 15. This leads to an abnormal fusion protein called promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) \[[@R04]\].

Case Report {#s2}
===========

A 41-year-old, previously healthy, Hispanic man presented to the emergency room with complains of headache, difficulty in speech and generalized weakness. Physical exam revealed heart rate of 86/min, respiratory rate of 16/min, afebrile, and neurological exam was relevant for expressive aphasia and right-sided facial droop. Complete blood count showed pancytopenia with white blood cell (WBC) of 600/µL (4,500 - 11,000/µL), hemoglobin of 7.3 g/dL (13.2 - 17.5 g/dL) and platelet count of 14,000/µL (140,000 - 450,000/µL). Computed tomography of head showed multiple intracranial hemorrhage. Due to pancytopenia, bone marrow biopsy (BMB) ([Figs. 1](#F1){ref-type="fig"}-[](#F2){ref-type="fig"}[](#F3){ref-type="fig"}[4](#F4){ref-type="fig"}) was done which showed hypocellular marrow, and there was presence of cells resembling promyelocytes. Flow cytometry ([Figs. 5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"}) showed increased blasts (86.8% of total cells) and was positive for CD117, CD13, CD33 and CD64, negative for CD34 and HLA-Dr. Further, fluorescence *in situ* hybridization (FISH) study was done which was negative for t(15;17) and showed no other mutations. Karyotype was 46,XY, t(2;20)(q21;q13.1), del(14)(q24) (20). Next generation sequencing (NGS) was negative. Molecular testing using polymerase chain reaction (PCR) was not performed at that time. Diagnosis of AML was made. He was started on systemic chemotherapy with idarubicin and cytarabine. On chemotherapy day 15, bone marrow biopsy was repeated, which showed hypocellular bone marrow with no overt evidence of acute leukemia suggesting remission. However, after 1 year, he had abnormal outpatient complete blood count and so BMB was repeated, and he was found to have relapsed disease. BMB showed 31% blasts along with t(15;17) fusion. Karyotype was 46,XY, t(2;20)(q21;q13.1), del(14)(q24) (20). Diagnosis of APL was made this time. Because of the unexpected results, original AML sample was retested with FISH probe. FISH for t(15;17) was negative at initial presentation. A cryptic t(15;17) fusion was identified by FISH at relapse 1 year later, confirmed with molecular testing using PCR. The karyotype at initial presentation is identical to that at relapse which supports that this is AML acquiring t(15;17) at relapse. Patient was treated with ATRA and ATO, to which he responded very well.

![Bone marrow biopsy showing hypocellular marrow for age (× 100).](wjon-10-153-g001){#F1}

![Bone marrow biopsy showing infiltration of marrow by monomorphic cells with fine chromatin and moderate amounts of granular cytoplasm (× 400).](wjon-10-153-g002){#F2}

![Bone marrow biopsy. Promyelocyte (blast equivalent) showing Auer rods and cytoplasmic coarse granules and fine chromatin (oil, × 1,000).](wjon-10-153-g003){#F3}

![Bone marrow biopsy. Promyelocyte with Auer rod marked with black arrow.](wjon-10-153-g004){#F4}

![Flow cytometry. The blasts show high side scatter indicating complex cytoplasm.](wjon-10-153-g005){#F5}

![Flow cytometry. The blasts are positive for CD117 and negative for CD34 and HLA-DR, highly suggestive of APL.](wjon-10-153-g006){#F6}

Discussion {#s3}
==========

Our patient was diagnosed to have APL at the time of relapse of AML. APL is cytogenetically characterized by the translocation in chromosomes 15 and 17 (t(15;17)). Translocation results in the fusion protein called PML-RARA which blocks the differentiation and maturation of myeloid cells at the promyelocytic stage.

Acquisition of PML-RARA as relapsed AML is rarely reported in literature. To the best of our knowledge, we found only one similar case reported by Vitale et al. In their case, it was hypothesized that there was a subclonal PML-RARA under detectable threshold and the subclone could have undergone selection during initial chemotherapy \[[@R05], [@R06]\]. Our patient also had acquisition PML-RARA as relapse of AML, after receiving 1 year of chemotherapy. Another possibility could be therapy-related APL secondary to chemotherapy \[[@R07]\]. APL can sometimes occur after cytotoxic therapy for another disease (e.g. breast cancer, lymphoma, other solid tumors), especially in association with the use of topoisomerase-II inhibitors such as etoposide and doxorubicin, or after radiation therapy \[[@R08]\]. Our patient was treated with topoisomerase-II inhibitor.

A recently published prospective analysis conducted by French-Belgian-Swiss APL group studied characteristics of *de novo* and secondary APLs \[[@R07]\]. Secondary APL arising after chemotherapy or radiotherapy constituted about 10-20% of all cases \[[@R07]\]. Secondary APL has also been reported more recently after mitoxantrone treatment for multiple sclerosis. As per the study, hematologic characteristics and outcomes of secondary APL were like those of *de novo* APL \[[@R07]\].

Giri et al conducted a population-based study, utilizing surveillance, epidemiology and end results (SEERs) database to compare the characteristics and survival of secondary APL and *de novo* APL. Study demonstrated no difference in overall survival (OS) between the two, suggesting that the underlying tumor biology of secondary APL and *de novo* APL is similar. At the same time, it was also suggested that both the entities can be managed similarly \[[@R9]\].

APL was first described in 1957 \[[@R01]\]. Independent risk factors for a diagnosis of APL in a patient with AML are younger age, Hispanic ethnicity and obesity \[[@R10]\]. Historically, as a fatal disease, now with recent advances, APL is considered a more curable disease. Patients with APL commonly present with symptoms related to complications of pancytopenia including weakness, fatigue, infection and hemorrhage. It is characterized by severe bleeding tendency due to fibrinogenemia and disseminated intravascular coagulation, accumulation of abnormal promyelocytes in bone marrow and peripheral blood \[[@R11]\]. Disruption of RARA function is the major cause of APL \[[@R12]\].

Secondary acquisition like in our patient is of a concern for a treating physician as the treatment may entirely change. Delay in administration of ATRA in cases of APL has been reported to be life-threatening. It is strongly recommended to start treatment with a differentiation agent without delay as soon as the diagnosis is suspected based on cytologic and clinical criteria, and before definitive genetic, cytogenetic, or immunostaining confirmation of the diagnosis has been made.

As addition of ATRA to chemotherapy leads to substantially improved outcomes, it is therefore very important to find better ways to diagnose cryptic oncogenes, especially related to APL. Welch et al studied the utility of whole genome sequencing (WSG) to diagnose a cryptic fusion oncogene \[[@R13]\]. As per their study, WSG can identify cytogenetically invisible oncogenes in a clinically relevant time frame. They described a patient with AML, who was initially being considered for allogeneic stem cell transplantation, and was instead treated with ATRA consolidation after conducting WSG \[[@R13]\]. Our patient underwent NGS at primary presentation which was negative. However, PCR was not performed at that time. While relapse, PCR for PML-RARA was positive.

Treatment of APL is based on risk stratification \[[@R02]\]. Low-risk disease is defined as WBC of ≤ 10,000/µL and high-risk disease as WBC ≥ 10,000/µL. For last few decades, ATRA + ATO-based therapy with or without chemotherapy is the backbone of management of APL. Whether or not to use chemotherapy is based on risk stratification of APL. Chemotherapy is usually omitted in low-risk disease \[[@R02]\]. Induction chemotherapy is still the standard of care for high-risk disease.

ATRA was introduced in 1985 \[[@R11]\]. It induces differentiation of leukemic promyelocytes to mature granulocytes. ATRA and ATO are synergistic in their action for inducing differentiation \[[@R02]\]. Using this combination therapy, complete remission (CR) rate up to 96% can be achieved. However, further studies showed that for high-risk disease inferior CR rate of 79-81% was achieved because of fatal hemorrhage and differentiation syndrome \[[@R11], [@R14]\]. Therefore, for high-risk disease, addition of cytotoxic drugs like anthracyclines is very important to prevent rapid development of leukocytosis, differentiation syndrome and relapse \[[@R15], [@R16]\].

Conclusion {#s3a}
----------

It is critical to screen patients for PML-RARA fusion in all AML cases, even in the setting of relapse. APL represents a medical emergency with a high rate of early mortality. Treatment with a differentiation agent should be started without delay as soon as the diagnosis is suspected based on cytologic criteria, and even before definitive cytogenetic or molecular confirmation of the diagnosis has been made.
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